Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Cancer Genetics' UroGenRA-Kidney Array


Cancer Genetics, a Rutherford, NJ-based provider of oncology-focused molecular testing services, recently introduced UroGenRA-Kidney, a microarray intended for kidney cancer diagnosis and subtyping.

According to the company, the test is being offered in compliance with the US Clinical Laboratory Improvement Amendment and the approval of the New York State Department of Health. CGI said that the test will be offered to clients as part of its Kidney Complete Program, a suite of tests for kidney cancer.

It claims that UroGenRA-Kidney can be used to subtype kidney cancer tissue samples among three malignant renal cell carcinoma subtypes – clear cell, papillary, and chromophobe, as well as a benign form of renal cancer, oncocytoma. The company additionally claims that the data generated by the array can be used to select the appropriate therapy based on the kidney cancer subtype.